<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934036</url>
  </required_header>
  <id_info>
    <org_study_id>HOPE_TRIAL1</org_study_id>
    <nct_id>NCT01934036</nct_id>
  </id_info>
  <brief_title>Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women</brief_title>
  <official_title>Efficacy and Safety of Obex®, a Nutritional Supplement, in Overweight or Obese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effects of a dietary supplement (Obex®) on
      anthropometric and physiological variables in Spanish women between 35 and 60 years who are
      overweight or obese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The nutritional supplement consists of natural plant extracts such as Caralluma fimbriata,
      Phaseolus vulgaris, Acai Berry and other antiobesity agents: ornithine, carnitine fumarate,
      essential fatty acids and certain amino acids, vitamins and minerals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of OBEX on skinfolds</measure>
    <time_frame>Two months of treatment and three months after concluded the treatment</time_frame>
    <description>The primary outcome is to evaluate the effect of the treatment with OBEX on skinfold thickness of the biceps, triceps, subscapular and suprailiac as compared to placebo group at 2 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of OBEX on the waist and hip circumferences</measure>
    <time_frame>Two months of treatment and three months after concluded the treatment</time_frame>
    <description>Waist and Hip circumferences will be measured at baseline and at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of Obex on the arm circumference.</measure>
    <time_frame>Two months of treatment and three months after concluded the treatment</time_frame>
    <description>The arm circumference will be measured at baseline and at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of Obex on the percentage of body fat</measure>
    <time_frame>Two months of treatment and three months after concluded the treatment</time_frame>
    <description>Body fat (%) will be assessed at baseline and the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of Obex on the muscular mass</measure>
    <time_frame>Two months of treatments and three months after concluded the treatment</time_frame>
    <description>The muscular mass will be measured at baseline and at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of Obex on arterial blood pressures.</measure>
    <time_frame>Two months of treatment and three months after concluded the treatment</time_frame>
    <description>The arterial BP will be evaluated at baseline and at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of Obex on fasting glucose and cholesterol levels</measure>
    <time_frame>Two months of treatment and three months after concluded the treatment</time_frame>
    <description>The fasting glucose and cholesterol levels will be evaluated at baseline and at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Obex, a nutritional supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Obex</intervention_name>
    <description>After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.</description>
    <arm_group_label>Obex, a nutritional supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged between 35 and 60 years.

          -  Body Mass Index (BMI) greater than 27 kg/m² and lower than 35 kg/m²

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Presence of any endocrine, hepatic, renal or cardiovascular disease.

          -  History of bariatric surgery

          -  Pregnancy or lactation

          -  Concomitant disease with reduced life expectancy

          -  Severe psychiatric conditions

          -  Drug dependence
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Consuelo Prado, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autonónoma de Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Autónoma de Madrid</name>
      <address>
        <city>Ciudad Universitaria de Cantoblanco</city>
        <state>Madrid</state>
        <zip>28049</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weight loss</keyword>
  <keyword>Nutritional supplement</keyword>
  <keyword>Waist</keyword>
  <keyword>Body composition</keyword>
  <keyword>Skinfolds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

